Previous 10 | Next 10 |
- Phase 3 REGAL Study of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) Patients Underway in United States and Europe - - License Agreement with 3D Medicines for Development and Commercialization of GPS in China Initiates Commercialization Strategy for GPS ...
Sellas Life Sciences ([[SLS]] +2.7%) has reported early data from two studies of galinpepimut-S ((GPS)), the Company’s Wilms Tumor-1 (WT1)-targeting peptide immunotherapeutic, in combination with checkpoint inhibitor therapies in patients with two different types of advanced solid canc...
- Early Data from Study of GPS in Combination with Keytruda ® in Patients with Advanced WT1(+) Ovarian Cancer Shows Disease Control Rate of 87.5% at a Median Follow-up of 9.4 Weeks and 100% Progression Free Survival at 6 Weeks - - Early Data from Mesothelioma Study of...
SELLAS Life Sciences Group (SLS) closes it's registered direct offering for net proceeds of ~$14.9M and ~$8.1M from outstanding warrants.Improved cash position will support clinical development programs for Galinpepimut-S, its lead late-stage clinical candidate, as well as its next gener...
- Proceeds Received from Registered Direct Offering, Warrant Exercises and Upfront Fee from China Out-licensing - - Improved Cash Position Will Support Clinical Development Programs for Galinpepimut-S - NEW YORK, Dec. 17, 2020 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group...
Gainers: BioCardia (BCDA) +102%.Arvinas (ARVN) +91%.Rubius Therapeutics (RUBY) +56%.Veru (VERU) +48%.AnPac Bio-Medical Science (ANPC) +45%.Homology Medicines (FIXX) +32%.ReneSola (SOL) +32%.Alexion Pharmaceuticals (ALXN) +31%.BioLineRx (BLRX) +30%.Big Rock Partners Acquisition (BRPA...
Gainers: Arvinas (ARVN) +97%, Rubius Therapeutics (RUBY) +95%, AnPac Bio-Medical Science (ANPC) +67%, Veru (VERU) +46%, BioCardia (BCDA) +31%.Losers: Aerpio Pharmaceuticals (ARPO) -47%, SELLAS Life Sciences (SLS) -27%, Greenwich Life...
SELLAS Life Sciences (SLS) inks agreement with institutional investors to sell 2.32M shares of its common stock at a purchase price of $7.00/share, for expected gross proceeds of ~$16.2M. Closing date is December 16. For further details see: Sellas Life Sciences prices $16.2M direct off...
NEW YORK, Dec. 13, 2020 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indicati...
Gainers: Sonoma Pharmaceuticals (SNOA) +87%.aTyr Pharma (LIFE) +65%.NantHealth (NH) +63%.vTv Therapeutics (VTVT) +55%.Equus Total Return (EQS) +45%Hancock Jaffe Laboratories (HJLI) +34%.MDJM (MDJH) +25%.Foresight Autonomous (FRSX) +23%.Solid Biosciences (SLDB) +22%.22...
News, Short Squeeze, Breakout and More Instantly...
SELLAS Life Sciences Group Inc. Company Name:
SLS Stock Symbol:
NASDAQ Market:
SELLAS Life Sciences Group Inc. Website:
2024-07-19 10:10:00 ET July 19, 2024 (Investorideas.com Newswire) Investorideas.com , a global news source and expert investing resource, announces today's roundup of stocks to watch in the Biotech, Cleantech Sectors. The newest biotech companies are involved in blood disorder treat...
- Acute Myeloid Leukemia (AML) is the Second Most Common Hematological Malignancy in Children Often Associated with Poorer Prognosis Compared to Other Pediatric Cancers – - This Recognition Marks SELLAS’ Second RPDD Following the Designation for ALL Received Last Month - -...
NEW YORK, July 08, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today ...